Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ruben Cruz

Psychiatry Meridian, MS Medical Doctor

NPI 1386796654 CMS profile 243995

1818 College Drive, Meridian, MS 39307

Open in the dashboard

General payments

$4,189

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ruben Cruz of Meridian, MS is reported in the CMS Open Payments database as having received $4,189 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $601 25
2024 General $708 31
2023 General $942 43
2022 General $767 31
2021 General $696 33
2020 General $129 7
2019 General $346 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ruben Cruz
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ruben Cruz were reported at $601. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ruben Cruz Psychiatry median Middle half National median
2019 $346 $184 $59–$605 $163
2020 $129 $119 $36–$372 $114
2021 $696 $143 $43–$576 $132
2022 $767 $153 $50–$590 $149
2023 $942 $170 $56–$651 $160
2024 $708 $179 $57–$673 $164
2025 $601 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $1,604 69 payments
  2. Janssen Pharmaceuticals, Inc $862 42 payments
  3. Otsuka America Pharmaceutical, Inc. $375 18 payments
  4. Vanda Pharmaceuticals Inc. $356 15 payments
  5. Neurocrine Biosciences, Inc. $268 7 payments
  6. Teva Pharmaceuticals USA, Inc. $201 11 payments
  7. Boston Scientific Corporation $165 1 payment
  8. Lundbeck LLC $143 7 payments
  9. E.R. Squibb & Sons, L.L.C. $127 6 payments
  10. ITI, Inc. $39 2 payments
  11. Other $48 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,189 181 payments
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $1,576 68 payments
  2. ARISTADA Cns $1,576 68 payments
  3. ARISTADA Cns $1,250 53 payments
  4. ARISTADA Cns $1,250 53 payments
  5. LYBALVI $1,247 51 payments
  6. INVEGA SUSTENNA $862 42 payments
  7. ARISTADA INITIO $684 33 payments
  8. ABILIFY MAINTENA $518 25 payments
  9. HETLIOZ $356 15 payments
  10. FANAPT $356 15 payments
  11. Other $1,472 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record